• Description
  • Programmes
  • Contact

Sectors: Health, Innovation, New technologies, Research

Beneficiaries: Corporations, Federations Unions, Research centres, Schools, SMEs, Universities

Regions: Balkans, Candidate countries, Developing countries, European Economic Area, European Union, Mediterranean countries, New Independant States, Switzerland

Category: Call for proposals


To view this information, please connect.

Additional info regions:

Numerous countries are eligible for funding under Horizon 2020, make sure you are eligible to apply.

Responsible: European Commission


To view this information, please connect.


To view this information, please connect.


To view this information, please connect.


IMI2 is a Joint Technology Initiative (JTI) that aims to improve the drug development process by supporting more efficient research and development cooperation among academia, small and medium enterprises (‘SMEs’) and the biopharmaceutical industry.

Priorities and funded actions:

Topic 1: Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and Health Technology Assessment bodie

Topic 2: Diabetic Kidney Disease Biomarkers (DKD-BM)

Topic 3: Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33

Topic 4: Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)

Topic 5: Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: Phased expansion study

Topic 6: From ApoE biology to validated Alzheimer’s disease targets